BioSpace News Archive

Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development and commercialization of innovative therapies for diseases and conditions of the eye, today announced the initiation of its first pivotal clinical trial to evaluate OTX-TKI, the Company’s axitinib intravitreal implant, for the treatment of wet age-related macular degeneration (wet AMD).

ProSomnus, Inc. announces management’s participation in the 2023 Roth Capital Healthcare Opportunities Conference at the Yale Club in New York City on October 12, 2023.

Akebia Therapeutics, Inc., a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted one newly-hired employee options to purchase an aggregate of 2,000 shares of Akebia’s common stock on September 29, 2023, as an inducement material to such employee entering into employment with Akebia.

Alimera Sciences, Inc., a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer, announced the appointment of Jason Werner, Chief Operating Officer, effective October 2, 2023.

Centessa Pharmaceuticals plc announced the appointment of April Dovholuk and Ellie Im, MD to Centessa’s executive team as Senior Vice President of Development Operations and Senior Vice President of Clinical Development, Oncology, respectively.

Galectin Therapeutics, Inc. today reported the positive outcome of its fourth data and safety monitoring board (DSMB) meeting for NAVIGATE, its seamless, adaptive, Phase 2b/3 study of belapectin in patients with portal hypertension caused by non-alcoholic steatohepatitis (NASH) liver cirrhosis.

STRATA Skin Sciences, Inc., a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, announced that the company will be participating in two medical conferences during October.

Spectral Medical Inc., a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, provided an update on the progress of its Tigris trial including patient enrollment and new trial site additions to further accelerate patient enrollment.

MBX Biosciences, Inc. today announced that results from the Phase 1 Study of MBX 2109, the company’s long-acting parathyroid hormone (PTH) peptide prodrug in development for the treatment of hypoparathyroidism (HP), will be featured in a late-breaking oral presentation at the American Society for Bone and Mineral Research (ASBMR) Annual Meeting being held in Vancouver, Canada October 13-16, 2023.

Syneos Health, Inc., a leading fully integrated biopharmaceutical solutions organization, announced that Colin Shannon has been appointed Chief Executive Officer, effective immediately.